Cargando…

Comparison of the Efficacy and Safety of Adalimumab (Humira) and the Adalimumab Biosimilar Candidate (HS016) in Chinese Patients with Active Ankylosing Spondylitis: A Multicenter, Randomized, Double-Blind, Parallel, Phase III Clinical Trial

OBJECTIVE: The aim of this study was to evaluate the efficacy and safety of the biosimilar candidate of adalimumab (HS016) compared with adalimumab (Humira) for the treatment of active ankylosing spondylitis. METHODS: A multicenter, randomized, double-blind, parallel, positive control, phase III cli...

Descripción completa

Detalles Bibliográficos
Autores principales:	Su, Jinmei, Li, Mengtao, He, Lan, Zhao, Dongbao, Wan, Weiguo, Liu, Yi, Xu, Jianhua, Xu, Jian, Liu, Huaxiang, Jiang, Lindi, Wu, Huaxiang, Zuo, Xiaoxia, Huang, Cibo, Liu, Xiumei, Li, Fen, Zhang, Zhiyi, Liu, Xiangyuan, Dong, Lingli, Li, Tianwang, Chen, Haiying, Li, Jingyang, He, Dongyi, Lu, Xin, Huang, Anbin, Tao, Yi, Wang, Yanyan, Zhang, Zhuoli, Wei, Wei, Li, Xiaofeng, Zeng, Xiaofeng
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2020
Materias:	Original Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7211209/ https://www.ncbi.nlm.nih.gov/pubmed/32078145 http://dx.doi.org/10.1007/s40259-020-00408-z

Ejemplares similares

Changes in Efficacy Indicators for Adalimumab Biosimilar Candidate (HS016) for the Treatment of Active Ankylosing Spondylitis at Various Time Points
por: Su, Jinmei, et al.
Publicado: (2020)

Evaluation of adalimumab biosimilar candidate (HS016) in Chinese patients with active ankylosing spondylitis based on a health survey: sub-analysis of a phase 3 study
por: Su, Jinmei, et al.
Publicado: (2021)

Adalimumab (Humira™) in Ophthalmology: A Review of the Literature
por: Neri, Piergiorgio, et al.
Publicado: (2010)

Adalimumab (Humira) induced acute lung injury
por: Kohli, Ritesh, et al.
Publicado: (2013)

Efficacy and safety of adalimumab biosimilar (HS016) in inflammatory bowel disease from the real-world study
por: Wang, Fang, et al.
Publicado: (2023)

Consistency of quality attributes for the glycosylated monoclonal antibody Humira® (adalimumab)
por: Tebbey, Paul W, et al.
Publicado: (2015)

Quality by Design–Based Assessment for Analytical Similarity of Adalimumab Biosimilar HLX03 to Humira®
por: Zhang, Erhui, et al.
Publicado: (2020)

Demonstration of physicochemical and functional similarity between the proposed biosimilar adalimumab MSB11022 and Humira®
por: Magnenat, Laurent, et al.
Publicado: (2016)

Physicochemical and biological similarity assessment of LBAL, a biosimilar to adalimumab reference product (Humira®)
por: Kwon, Joon-Cheol, et al.
Publicado: (2021)

A comparative clinical study of PF-06410293, a candidate adalimumab biosimilar, and adalimumab reference product (Humira®) in the treatment of active rheumatoid arthritis
por: Fleischmann, Roy M., et al.
Publicado: (2018)

Comparison of the pharmacokinetics, safety, and immunogenicity of MSB11022, a biosimilar of adalimumab, with Humira(®) in healthy subjects
por: Hyland, Elizabeth, et al.
Publicado: (2016)

Pharmacokinetic equivalence, comparable safety, and immunogenicity of an adalimumab biosimilar product (M923) to Humira in healthy subjects
por: Hillson, Jan, et al.
Publicado: (2018)

The Expiry of Humira(®) Market Exclusivity and the Entry of Adalimumab Biosimilars in Europe: An Overview of Pricing and National Policy Measures
por: Moorkens, Evelien, et al.
Publicado: (2021)

TNF-α Promoter Polymorphisms Predict the Response to Etanercept More Powerfully than that to Infliximab/Adalimumab in Spondyloarthritis
por: Liu, Jing, et al.
Publicado: (2016)

Comparative evaluation of efficacy, pharmacodynamics, and safety of Hetero’s adalimumab (Mabura®, Hetero Biopharma Ltd.) and reference adalimumab (Humira®, Abbvie Inc.) in patients with active rheumatoid arthritis on concomitant methotrexate therapy
por: Sinha, Shubhadeep, et al.
Publicado: (2020)

Impact of Participation in the Adalimumab (Humira) Patient Support Program on Rheumatoid Arthritis Treatment Course: Results from the PASSION Study
por: Van den Bosch, Filip, et al.
Publicado: (2017)

A prospective, randomized, double‐blind, multicentre, parallel‐group, active controlled study to compare efficacy and safety of biosimilar adalimumab (Exemptia; ZRC‐3197) and adalimumab (Humira) in patients with rheumatoid arthritis
por: Jani, Rajendrakumar H., et al.
Publicado: (2015)

Erratum to: Impact of Participation in the Adalimumab (Humira) Patient Support Program on Rheumatoid Arthritis Treatment Course: Results from the PASSION Study
por: Van den Bosch, Filip, et al.
Publicado: (2017)

Adalimumab (Humira®) Induced Recurrent Peritonsillar Abscess in A Patient Received Three Different Anti-TNF Therapies: A Case Report
por: Vural, Sevilay, et al.
Publicado: (2022)

A Randomized, Double‐Blind, Parallel‐Group, Phase 1 Clinical Trial Comparing the Pharmacokinetic, Safety, and Immunogenicity of the Biosimilar HS016 and the Originator Adalimumab in Chinese Healthy Male Subjects
por: Cao, Guoying, et al.
Publicado: (2020)

Influence of information provided prior to switching from Humira to biosimilar adalimumab on UK patients’ satisfaction: a cross-sectional survey by patient organisations
por: Kaneko, Kayoko, et al.
Publicado: (2022)

Adalimumab in Treating Refractory Livedoid Vasculopathy
por: Huang, Xiao-Wen, et al.
Publicado: (2022)

Adalimumab for treatment of very early onset inflammatory bowel disease
por: Xie, Yao, et al.
Publicado: (2019)

Demonstration of Physicochemical and Functional Similarity of Biosimilar Adalimumab-aqvh to Adalimumab
por: Jiang, Yijia, et al.
Publicado: (2023)

Adalimumab for the treatment of cardiac sarcoidosis with multiple arrhythmias
por: Li, Sitong, et al.
Publicado: (2022)

Safety and Efficacy of Prefilled Liquid Etanercept-Biosimilar Yisaipu for Active Ankylosing Spondylitis: A Multi-Center Phase III Trial
por: Zhao, Dongbao, et al.
Publicado: (2021)

Adalimumab in Vogt-Koyanagi-Harada Disease Refractory to Conventional Therapy
por: Yang, Shizhao, et al.
Publicado: (2022)

The Efficacy of Adalimumab as an Initial Treatment in Patients with Behçet’s Retinal Vasculitis
por: Yang, Shizhao, et al.
Publicado: (2021)

Adalimumab and anti-adalimumab LISA-TRACKER immunoassays performance criteria for therapeutic drug monitoring of adalimumab-amgen biosimilar (ABP501)
por: Francois, Fabien, et al.
Publicado: (2021)

Treating psoriasis with adalimumab
por: Alwawi, Eihab A, et al.
Publicado: (2008)

Adalimumab in the treatment of arthritis
por: Mease, Philip J
Publicado: (2007)

Adalimumab in Crohn’s disease
por: Van Assche, Gert, et al.
Publicado: (2007)

Efficacy of adalimumab in sarcoidosis
por: Kamphuis, LSJ, et al.
Publicado: (2010)

Long-term efficacy, safety, and immunogenicity of the adalimumab biosimilar, PF-06410293, in patients with rheumatoid arthritis after switching from reference adalimumab (Humira®) or continuing biosimilar therapy: week 52–92 data from a randomized, double-blind, phase 3 trial
por: Fleischmann, Roy M., et al.
Publicado: (2021)

Addition of Cyclosporine to Adalimumab Improved Psoriasis And Adalimumab-Induced Injection Site Reaction
por: Nakamizo, Satoshi, et al.
Publicado: (2014)

Reactive Arthritis Triggered by Adalimumab and Leflunomide in a Patient with Ankylosing Spondylitis
por: Liu, Ying, et al.
Publicado: (2022)

Adalimumab biosimilars, ABP501 and SB5, are equally effective and safe as adalimumab originator
por: Cingolani, Linda, et al.
Publicado: (2021)

Contextualizing the Price of Biosimilar Adalimumab Based on Historical Rebates for the Original Formulation of Branded Adalimumab
por: Dickson, Sean R., et al.
Publicado: (2023)

Assessing Analytical Similarity of Proposed Amgen Biosimilar ABP 501 to Adalimumab
por: Liu, Jennifer, et al.
Publicado: (2016)

Adalimumab for the treatment of Crohn’s disease
por: Cassinotti, Andrea, et al.
Publicado: (2008)

Cannot write session to /tmp/vufind_sessions/sess_hpqntaat6u3pda61g1ivfg3rk9